Ajanta Pharma Limited
Ajanta Pharma Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹1,794 cr of revenue in its latest quarter (Q2 FY27) and kept 21.6% of sales as profit.
Healthier than 72% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 37–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 42
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in AJANTPHARM?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 0%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹1,794 cr |
| Other Income | ₹37 cr |
| Total Income | ₹1,832 cr |
| Cost of Materials | ₹349 cr |
| Purchases of Stock-in-Trade | ₹81 cr |
| Inventory Change (±) | ₹-45 cr |
| Employee Benefit Expense | ₹384 cr |
| Finance Costs | ₹2 cr |
| Depreciation & Amortisation | ₹48 cr |
| Other Expenses | ₹478 cr |
| Total Expenses | ₹1,296 cr |
| Profit before Tax | ₹535 cr |
| Tax Expense | ₹147 cr |
| Net Profit | ₹388 cr |
| Net margin on total income | 21.2% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 1,422 cr | 1,626 cr | 1,794 cr |
| Total income | 1,483 cr | 1,697 cr | 1,832 cr |
| Expenses | 1,136 cr | 1,250 cr | 1,296 cr |
| Profit before tax | 347 cr | 447 cr | 535 cr |
| Tax | 80 cr | 113 cr | 147 cr |
| Net profit (owners' share) | 267 cr | 330 cr | 388 cr |
| Net margin (owners' share, on revenue) | 18.8% | 20.3% | 21.6% |
| EPS (₹) | 21.35 | 26.75 | 31.07 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹32 / share | 5 Aug 2026 |
| Dividend | ₹28 / share | 10 Nov 2025 |
| Dividend | ₹28 / share | 6 Nov 2024 |
| Buyback | Buy Back of Shares | 30 May 2024 |
| Dividend | ₹26 / share | 8 Feb 2024 |
| Dividend | ₹15 / share | 4 Aug 2023 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 22 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.